Are newer, targeted agents better for the management of untreated CLL than chemoimmunotherapy?

The targeted agent ibrutinib has been tested as a first-line monotherapy in elderly chronic lymphocytic leukemia (CLL) in the RESONATE-2 trial (NCT01722487); however, within CLL, it has not been teste... Author: VJHemOnc Added: 01/08/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts